The Serine/Threonine Protein Kinase B Raf pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase B Raf targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Serine/Threonine Protein Kinase B Raf pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Genetic Disorders, Dermatology, and Ear Nose Throat Disorders which include the indications Solid Tumor, Non-Small Cell Lung Cancer, Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Kabuki Syndrome, Acne And Related Disorders, Wounds, and Hearing Disorders. It also reviews key players involved in Serine/Threonine Protein Kinase B Raf targeted therapeutics development with respective active and dormant or discontinued products.
The Serine/Threonine Protein Kinase B Raf pipeline targets constitutes close to 48 molecules. Out of which, approximately 39 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 8, 12, 8, 1, 8, and 1 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 7, and 2 molecule.
Serine/Threonine Protein Kinase B Raf overview
Serine/threonine-protein kinase B-Raf (BRAF) is a critical enzyme involved in the mitogen-activated protein kinase (MAPK) signaling pathway, which plays a crucial role in regulating cell growth, proliferation, and differentiation. BRAF functions as a kinase, transferring phosphate groups to specific serine and threonine residues on target proteins, thereby altering their activity and downstream signaling events.
For a complete picture of Serine/Threonine Protein Kinase B Raf’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
